| Literature DB >> 16229772 |
Wei Liu1, Fang Tang, Arnaud Fontanet, Lin Zhan, Tian-Bao Wang, Pan-He Zhang, Yi-He Luan, Chao-Yang Cao, Qiu-Min Zhao, Xiao-Ming Wu, Zhong-Tao Xin, Shu-Qing Zuo, Laurence Baril, Astrid Vabret, Yi-Ming Shao, Hong Yang, Wu-Chun Cao.
Abstract
Single nucleotide variations (SNVs) at 5 loci (17564, 21721, 22222, 23823, and 27827) were used to define the molecular epidemiologic characteristics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) from Beijing patients. Five fragments targeted at the SNV loci were amplified directly from clinical samples by using reverse transcription-polymerase chain reaction (RT-PCR), before sequencing the amplified products. Analyses of 45 sequences obtained from 29 patients showed that the GGCTC motif dominated among samples collected from March to early April 2003; the TGTTT motif predominanted afterwards. The switch from GGCTC to TGTTT was observed among patients belonging to the same cluster, which ruled out the possibility of the coincidental superposition of 2 epidemics running in parallel in Beijing. The Beijing isolates underwent the same change pattern reported from Guangdong Province. The same series of mutations occurring in separate geographic locations and at different times suggests a dominant process of viral adaptation to the host.Entities:
Mesh:
Year: 2005 PMID: 16229772 PMCID: PMC3310602 DOI: 10.3201/eid1109.040773
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Primers used for nested polymerase chain reaction and sequencing
| Position | Amplification region* | Primer sets (starting from 5´) | |
|---|---|---|---|
| 17564 | 17440–18281 | Forward | ACGTCTATATTGGCGATCCT TGTGCAGACTTATGAAAACAATA |
| Reverse | GTTTTGCATTAACTCTGGTG GTTAGTACCCACAGCATCTCTAGT | ||
| 21721 | 21585–22304 | Forward | GATGATGTTCAAGCTCCTAATTAC CTTAACAGAGCATTTGAGTTCAG |
| Reverse | CAACATACTTCATCTATGAGGGG TGTACCATTTTCATCATACTTGAG | ||
| 22222 | 22177–22874 | Forward | AGATGTAGTTCGTGATCTACCTTC TTAATGGCCAATAACAATTAAGA |
| Reverse | CAAATTTTAGAGCCATTCTTACAG GGAGAAAGGCACATTAGATATGTC | ||
| 23823 | 23455–24263 | Forward | CGACACTTCTTATGAGTGCG ATGCAGTTGATGTTGTTGTAAG |
| Reverse | GCATTTGTGCTAGTTACCATACAG TGATGTTGTTGTAAGTGATTCTTG | ||
| 27827 | 27449–28270 | Forward | CCATCAGGAACATACGAGG GACCACTATTGGTGTTGATTG |
| Reverse | TAGCACACACTTTGCTTTTG CAGTATTATTGGGTAAACCTTGG | ||
*The nucleotide position was given with TOR2 as the reference strain (accession no. NC004718).
Epidemiologic and phylogenetic data on 29 severe acute respiratory syndrome patients, Beijing, 2003*
| Patient no. (sex, age [y]) | Onset date† | Sampling date,† clinical sample | 5-loci genotype | Other variant loci |
|---|---|---|---|---|
| 1‡ (M, 25) | 3/10 | 4/28, Sp | GGCTC | 22589 |
| 2‡§ (F, 48) | 3/21 | 4/28, Sp | GGCTC | 22589, 27749 |
| 3 (M, 19) | 3/31 | 4/28, Sp; 5/5, Sp | GGCTC | 22589 |
| 4‡ (F, 34) | 3/31 | 5/5, St; 4/28, Sp | TGTTT | 17620, 22589 |
| 5‡§ (M, 21) | 3/31 | 4/28, Sp; 5/5, Sp | TGTTT | 22589 |
| 6‡ (F, 34) | 4/2 | 4/28, Sp | TGTTT | 22077 |
| 7 (F, 27) | 4/2 | 4/28, Sp | GGCTC | 22589 |
| 8‡ (M, 31) | 4/3 | 4/28, Sp | TGTTT | 22077, 22589, 27749 |
| 9‡ (M, 20) | 4/5 | 5/5, Sp; 4/28, Sp | TGTTT | 17620, 22077, 22589 |
| 10 (F, 23) | 4/8 | 5/22, St; 5/15, Sp | GGCTC | 22589 |
| 11§ (M, 47) | 4/8 | 5/5-Sp; 5/5, St | GGCTC | 22589 |
| 12 (M, 73) | 4/9 | 4/28, Sp; 4/28, St | TGTTT | 22589, 27749 |
| 13 (M, 54) | 4/9 | 4/28, Sp; 4/28, St | GGCTC | 22589, 27749 |
| 14‡ (F, 21) | 4/11 | 4/28, Sp; 4/28, St; 5/5, Sp | TGTTT | |
| 15§ (M, 61) | 4/12 | 5/22, Sp | GATTC | 22589 |
| 16‡ (F, 25) | 4/15 | 5/5, Sp | TGTTT | 17620, 22589, 27749 |
| 17 (M, 25) | 4/17 | 5/5, Sp | TGTTT | 22077, 22589, 27749 |
| 18 (F, 20) | 4/18 | 4/28, Sp; 4/28, St | TGTTT | 22589, 27749 |
| 19‡ (F, 25) | 4/20 | 5/5, Sp; 5/5, St | TGTTT | 22077, 22589, |
| 20 (F, 34) | 4/21 | 4/28, Sp; 5/5, Sp | TGTTT | 22077 |
| 21 (M, 33) | 4/23 | 5/5, Sp; 5/5 St; 4/28-Sp | TGTTT | 17620, 22589 |
| 22 (M, 28) | 4/24 | 5/5, Sp | TGTTT | 22589, 27749 |
| 23 (M, 61) | 5/1 | 5/15, Sp | GATTC | 22589 |
| 24‡ (F, 31) | 5/1 | 5/5, Sp | TGTTT | 22077, 2589, 7749 |
| 25 (M, 25) | 5/2 | 5/7, Sp | TGTTT | 22077 |
| 26‡ (M, 25) | 5/4 | 5/22, Sp | TGTTT | 22077 |
| 27 (M, 19) | 5/6 | 5/22, Sp | TGTTT | 22589, 27749 |
| 28 (F, 28) | 5/7 | 5/22, Sp | TGTTT | 17620, 22589, 27749 |
| 29 (M, 22) | 5/12 | 4/28, Sp; 5/5, Sp | TGTTT | 22589, 27749 |
*F, female; M, male; Sp, sputum; St, stool. †All dates are in 2003. ‡Patients were from the same cluster. §Patients with adverse clinical outcome.
Characterization of nucleotide (nt) substitutions in 29 severe acute respiratory syndrome patients, Beijing, China*
| ORF or protein | Position† | nt substitution | aa change | No. patients |
|---|---|---|---|---|
| ORF 1b | 17620 | C→T | Leu→Ser | 5 |
| S protein | 22077 | G→T | Phe→Tyr | 9 |
| S protein | 22589 | C→T | Noncoding region | 24 |
| ORF 9 | 27749 | G→A | Lys→Glu | 12 |
*SARS, severe acute respiratory syndrome; ORF, open reading frame; aa, amino acid. †The nt positions are numbered with TOR2 as reference strain (accession no. NC_004718).
Figurepidemiologic and phylogenetic links between patients of different worldwide SARS outbreaks (,,,). New information that concerns the Beijing epidemic is represented in boldface. Epidemiologic links that are still speculative are in dotted lines.